huh? this stock has merits, i had a good look but certainly nowhere near 50c (when i looked) or 40c where it is now. one to watch as they post the quarterlies
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling